Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultra-Processed Foods and Gastrointestinal Cancer: Epidemiologic Evidence, Mechanistic Pathways, and Clinical Implications.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Subcutaneous Delivery of Amivantamab in Patients With Advanced Solid Malignancies: The Phase Ib PALOMA Study.

Clinical lung cancer·2026
Same author

Circulating Inflammatory and Mitochondrial Biomarkers Associated with Cachexia in Advanced Non-Small Cell Lung Cancer.

Cancers·2026
Same author

CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (<i>NRG1</i>) Fusions.

JCO precision oncology·2025
Same author

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States.

Advances in therapy·2025

Related Experiment Video

Updated: Jun 11, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K

Emerging Targets in Non-Small Cell Lung Cancer.

Louisa Liu1, Joshua Soler2, Karen L Reckamp1

  • 1Samuel-Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

International Journal of Molecular Sciences
|September 28, 2024
PubMed
Summary
This summary is machine-generated.

New molecular targets are revolutionizing non-small cell lung cancer (NSCLC) treatment. This review details emerging targets, their mechanisms, and ongoing clinical trials for advanced NSCLC patients.

Keywords:
non-small cell lung cancernovel combinatorial approachesoncogene drivertargeted therapies

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.5K

Related Experiment Videos

Last Updated: Jun 11, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.5K

Area of Science:

  • Oncology
  • Genomics
  • Pharmacology

Background:

  • Lung cancer presents a significant global health burden.
  • Targetable genomic alterations have transformed non-small cell lung cancer (NSCLC) treatment.
  • Emerging molecular drivers offer new therapeutic avenues.

Purpose of the Study:

  • To review emerging molecular targets in advanced NSCLC.
  • To elaborate on their clinical characteristics and mechanisms.
  • To summarize ongoing clinical trials and preliminary efficacy data.

Main Methods:

  • Literature review of emerging molecular targets in NSCLC.
  • Analysis of clinical characteristics and molecular pathways.
  • Compilation of data from ongoing clinical trials.

Main Results:

  • Identified KRAS non-G12C, RAF/MEK, HER3, Nectin-4, folate receptor alpha, ITGB6, and PRMT5 as key emerging targets.
  • Detailed their specific mechanisms and targeted treatment availability.
  • Aggregated data on clinical trial status and preliminary efficacy.

Conclusions:

  • Emerging molecular targets show significant potential for advanced NSCLC.
  • Ongoing clinical trials are crucial for validating these targets.
  • These advancements can guide future NSCLC treatment strategies and improve patient outcomes.